In February the FDA removed cardiovascular, breast cancer and dementia risk statements from the boxed warning on six menopausal hormone therapy products, while the endometrial cancer warning remains on systemic estrogen-alone products for women with a uterus. The regulatory shift arrives against a documented preparation gap: only 6.8% of residents in one 2019 survey felt equipped to manage menopause, and women remain under-represented in the pharmacological evidence base. The argument advanced is that midlife female physiology needs a single integrated clinical view rather than sequential referrals.
Key Points
- FDA removed cardiovascular, cancer and dementia statements from hormone therapy warnings
- Only 6.8% of surveyed residents felt prepared to manage menopause
- Of 86 drugs reviewed, 76 reached higher concentrations in women
Longevity Analysis
Menopause is registered as a gynecological event but its consequences are distributed — accelerated bone loss signalled by anti-Müllerian hormone decline, faster reductions in brain glucose metabolism during perimenopause, and cardiovascular risk that shifts across the transition. Fragmenting that physiology across four specialists means each clinician sees a fraction of the signal and the pattern goes unread. The regulatory change restores an option; the harder work is interpreting a woman's timeline as a single continuous document and acting on it early enough to matter.
Original published by Longevity.Technology, by Eleanor Garth.